Literature DB >> 33505791

Soluble expression and purification of Bluetongue Virus Type 1 (BTV1) structure protein VP2 in Escherichia coli and its immunogenicity in mice.

Aiping Wang1, Jiajia Yin1, Jingming Zhou1, Hongfang Ma1, Yumei Chen1, Hongliang Liu1, Yanhua Qi1, Chao Liang1, Yankai Liu1, Jinge Li1, Gaiping Zhang1.   

Abstract

BACKGROUND: The VP2 on the surface of the virus particle is the main structural protein of BTV, which can induce the host to produce neutralizing antibodies and play an important role in the antiviral immunity process. This study aimed to obtain the soluble VP2 and analyze its immunogenicity.
METHODS: The gene encoding the full-length VP2 of BTV1 was amplified by PCR. The products from restriction enzyme digestion and ligase reaction between VP2 and vector pET-28a were transformed into E.coli DH5α. After PCR and sequencing detection, the positive plasmid PET28a-VP2 was transformed into E.coli BL21(DE3) and Rosetta(DE3) competent cells, expression induced by IPTG. The fusion protein was expressed in the optimized conditions with the induction of IPTG, purified by affinity chromatography and identified by SDS-PAGE and Western blotting. A total of 5 Balb/c mice aged 6-8 weeks were immunized with the fusion protein at a dose of 30 µg per mouse. Each mouse was immunized three times at an interval of 3 weeks.
RESULTS: The recombinant plasmid PET28a-VP2 was successfully constructed. The expression strains were induced by 0.4 mmol/L IPTG at 16 °C for 10 h, and BTV1 VP2 was expressed in a soluble form. The purity of the recombinant VP2 protein (∼109 kDa) was about 90% in the concentration at 0.2 mg/ml afterpurification. The purified VP2 had good immunoreactivity with BTV1 positive serum. Taken together, thisstudy offered a route for producing soluble BTV VP2, which retains activity and immunogenicity, to bebeneficial to the research on developing BTV vaccine, and lay the foundation for further research on BTV. ©2021 Wang et al.

Entities:  

Keywords:  Immunogenicity; Recombinant protein VP2; Solubility; Bluetongue virus

Year:  2021        PMID: 33505791      PMCID: PMC7789859          DOI: 10.7717/peerj.10543

Source DB:  PubMed          Journal:  PeerJ        ISSN: 2167-8359            Impact factor:   2.984


  26 in total

1.  Possible adverse reactions in sheep after vaccination with inactivated BTV vaccines.

Authors:  J M González; L Figueras; M E Ortega; M Lozano; M Ruiz de Arcaute; R Royo; L M Cebrián; L M Ferrer; F Fariñas; J A García de Jalón; M De las Heras
Journal:  Vet Rec       Date:  2010-06-12       Impact factor: 2.695

2.  An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy.

Authors:  G Savini; G F Ronchi; A Leone; A Ciarelli; P Migliaccio; P Franchi; M T Mercante; A Pini
Journal:  Vet Microbiol       Date:  2007-04-08       Impact factor: 3.293

3.  Expression of the polyomavirus VP2 and VP3 proteins in insect cells: coexpression with the major capsid protein VP1 alters VP2/VP3 subcellular localization.

Authors:  S E Delos; L Montross; R B Moreland; R L Garcea
Journal:  Virology       Date:  1993-05       Impact factor: 3.616

4.  Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10 using a baculovirus expression vector.

Authors:  S Inumaru; P Roy
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

5.  Bluetongue serotype 2 and 9 modified live vaccine viruses as causative agents of abortion in livestock: a retrospective analysis in Italy.

Authors:  G Savini; A Lorusso; C Paladini; P Migliaccio; A Di Gennaro; A Di Provvido; M Scacchia; F Monaco
Journal:  Transbound Emerg Dis       Date:  2012-09-03       Impact factor: 5.005

6.  Immune response against the purified serotype specific antigen of bluetongue virus and initial attempts to clone the gene that codes for the synthesis of this protein.

Authors:  H Huismans; N T van der Walt; B J Erasmus
Journal:  Prog Clin Biol Res       Date:  1985

7.  Identification of the serotype-specific and group-specific antigens of bluetongue virus.

Authors:  H Huismans; B J Erasmus
Journal:  Onderstepoort J Vet Res       Date:  1981-06       Impact factor: 1.792

8.  Identification and differentiation of the twenty six bluetongue virus serotypes by RT-PCR amplification of the serotype-specific genome segment 2.

Authors:  Narender S Maan; Sushila Maan; Manjunatha N Belaganahalli; Eileen N Ostlund; Donna J Johnson; Kyriaki Nomikou; Peter P C Mertens
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

9.  Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress.

Authors:  Bishnupriya Bhattacharya; Rob J Noad; Polly Roy
Journal:  Virol J       Date:  2007-01-15       Impact factor: 4.099

10.  Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect α/β interferon-receptor knock-out (IFNAR(-/-)) mice from homologous lethal challenge.

Authors:  Fauziah Mohd Jaafar; Mourad Belhouchet; Damien Vitour; Micheline Adam; Emmanuel Breard; Stéphan Zientara; Peter P C Mertens; Houssam Attoui
Journal:  Vaccine       Date:  2014-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.